Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
4.1
3.0
Journals
JPM
Special Issues
Clinical Science and Personalized Laboratory Medicine
share announcement

Clinical Science and Personalized Laboratory Medicine

A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Clinical Medicine, Cell, and Organism Physiology".

Deadline for manuscript submissions: closed (15 March 2023) | Viewed by 3752

Special Issue Editors

Dr. Abdurrahman Coskun

E-Mail Website
Guest Editor
Department of Medical Biochemistry, School of Medicine, Acibadem Mehmet Ali Aydinlar University, Istanbul, Turkey
Interests: personalized laboratory medicine; biological variation; reference intervals; measurement uncertainty; biochemistry
Dr. Ali Zarrabi

E-Mail Website
Guest Editor
Biomedical Engineering Department, Faculty of Engineering and Natural Sciences, Istinye University, Istanbul 34396, Turkey
Interests: nanomedicine; theranpstics; diagnosis; therapy; drug delivery systems; cancer; neurodegenerative disease; miRNA; siRNA; wound healing; biomedical engineering; biomaterials
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Clinicians use laboratory test results for diagnosis, monitoring, screening, case finding, planning, and treatment evaluation, and consequently, they usually make clinical decisions based on laboratory test results. For clinical decisions, clinicians compare patients’ test results to cutoff limits or reference data; however, these cutoff limits or reference data are derived from population-based studies, and therefore, individuals are considered as members of the population rather than as individuals. Furthermore, many commonly requested analytes show marked individuality; therefore, the cutoff limits or data derived from population studies may not be reliable for individuals.

Various factors such as sex, age, ethnicity, epigenetic changes, genetic characteristics, nutritional status, and environmental exposure make up and characterize individuals. Because everyone is unique at the behavioral, physiological, and molecular levels, the clinical findings and development of diseases will vary among individuals. Therefore, the diagnosis and treatment of diseases should be individualized.

Personalized laboratory medicine is an essential part of personalized medicine that is based on changes in the biomarker profiles characterizing an individual status, rather than changes in the concentration of a single biomarker; therefore, the success of personalized laboratory medicine depends on the use of advanced omics (such as genomics, proteomics, transcriptomics, metabolomics, epigenomics, pharmaco-genomics, etc.) technologies to create the molecular profiles of individuals and the availability of relevant and reliable personalized reference intervals.

Through this Special Issue, we invite researchers to contribute papers that present novel findings across all aspects of “Personalized Laboratory Medicine”. The aim is to collect the latest research/review manuscripts related to personalized laboratory medicine, integrating personalized laboratory medicine with personalized clinical sciences to facilitate a personalized approach to diseases from diagnosis to treatment.

Dr. Abdurrahman Coskun
Dr. Ali Zarrabi
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • advanced omics technologies
  • pharmacogenomics
  • personalized decision limits for disease diagnosis
  • personalized reference intervals
  • personalized reference change value (RCV)
  • personalized treatment and monitoring of individuals
  • management of patients with malignant disease
  • targeted therapy
  • nanomedicine and personalized medicine
  • wearable technology and personalized diagnosis
  • personalized health monitoring
  • theranostics and personalized medicine

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

12 pages, 650 KiB  
Article
Assessment of Amikacin- and Capreomycin-Related Adverse Drug Reactions in Patients with Multidrug-Resistant Tuberculosis and Exploring the Role of Genetic Factors
by Lauma Freimane, Linda Barkāne, Agnija Kivrane, Darja Sadovska, Viktorija Ulanova and Renāte Ranka
J. Pers. Med. 2023, 13(4), 599; https://doi.org/10.3390/jpm13040599 - 29 Mar 2023
Viewed by 1745
Abstract
Following the introduction of all-oral treatment regimens for patients with drug-resistant tuberculosis (TB), second-line injectable drug applications have been reduced in the last few years. However, they are still important for anti-TB therapy. This study aims to analyze the occurrence of amikacin- and [...] Read more.
Following the introduction of all-oral treatment regimens for patients with drug-resistant tuberculosis (TB), second-line injectable drug applications have been reduced in the last few years. However, they are still important for anti-TB therapy. This study aims to analyze the occurrence of amikacin- and capreomycin-related adverse drug reactions (ADR) in patients with multidrug-resistant tuberculosis (MDR-TB) and evaluate the role of multiple patient-, disease-, and therapy-related factors on the frequency of the observed adverse events. In addition, the possible role of genetic risk factors was studied by full-length mitochondrial DNA sequencing. Toward this aim, we retrospectively evaluated 47 patients with MDR-TB who received amikacin and/or capreomycin. In total, 16 (34.0%) patients developed ototoxicity and 13 (27.7%) developed nephrotoxicity, including 3 (6.4%) patients who experienced both adverse events. Ototoxicity development was more common in patients who received amikacin. No other factors showed a significant impact. Nephrotoxicity was likely associated with previous renal health impairment. Full mitochondrial genome sequencing did not reveal any specific ADR-associated variants, and results showed no differences in adverse event occurrence for any specific variants, mutation count, or mitochondrial haplogroup. The absence of the previously reported ototoxicity-related mtDNA variants in our patients with ototoxicity and nephrotoxicity highlighted the complex nature of the ADR occurrence. Full article
(This article belongs to the Special Issue Clinical Science and Personalized Laboratory Medicine)
►▼ Show Figures

Figure 1

13 pages, 1639 KiB  
Article
Urine Immunoglobin G Greater Than 2.45 mg/L Has a Correlation with the Onset and Progression of Diabetic Kidney Disease: A Retrospective Cohort Study
by Cheng Meng, Jiujing Chen, Xiaoyue Sun, Shilin Guan, Hong Zhu, Yongzhang Qin, Jingyu Wang, Yongmei Li, Juhong Yang and Baocheng Chang
J. Pers. Med. 2023, 13(3), 452; https://doi.org/10.3390/jpm13030452 - 28 Feb 2023
Cited by 1 | Viewed by 1571
Abstract
Aim: To further assess the correlation between urine immunoglobin G (IgG) greater than 2.45 mg/L and the onset and progression of diabetic kidney disease (DKD). Methods: One thousand and thirty-five patients with type 2 diabetes mellitus (T2DM) were divided into two groups based [...] Read more.
Aim: To further assess the correlation between urine immunoglobin G (IgG) greater than 2.45 mg/L and the onset and progression of diabetic kidney disease (DKD). Methods: One thousand and thirty-five patients with type 2 diabetes mellitus (T2DM) were divided into two groups based on the baseline levels of 24 h urinary albumin excretion (24 h UAE): one group with 24 h UAE < 30 mg/24 h and one with 24 h UAE ≥ 30 mg/24 h. The groups were subdivided using baseline levels of urine IgG (≤2.45 mg/L and >2.45 mg/L; hereafter, the Low and High groups, respectively). We used logistic regression to assess the risk of urine IgG and it exceeding 2.45 mg/L. Kaplan–Meier curves were used to compare the onset and progression time of DKD. The receiver operating characteristic curve was used to test the predictive value of urine IgG exceeding 2.45 mg/L. Results: Urine IgG was an independent risk factor for the onset and progression of DKD. The rate and risk of DKD onset and progression at the end of follow-up increased significantly in the High group. The onset and progression time of DKD was earlier in the High group. Urine IgG exceeding 2.45 mg/L has a certain predictive value for DKD onset. Conclusions: Urine IgG exceeding 2.45 mg/L has a correlation with the onset and progression of DKD, and it also has a certain predictive value for DKD onset. Full article
(This article belongs to the Special Issue Clinical Science and Personalized Laboratory Medicine)
►▼ Show Figures

Graphical abstract

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop